I just closed my blog’s poll on what are the most clinically promising pluripotent stem cells. Why close the poll now less than 12 hours after I opened it instead of leaving the poll open longer? You’ll find out soon enough. I can’t resist teasing you readers sometimes. iPS cells were the big winners in …
iPS cells top poll as most clinically promising pluripotent stem cells Read More »
Will intellectual property (IP) wars over patent rights to one of the most exciting new stem cell technologies hold back getting novel therapies to patients such as IPS cells? Unfortunately, it’s very possible. Induced pluripotent stem (iPS) cells are very cool stem cells made from non-stem cells through a process called cellular reprogramming. iPS cells …
Putting the IP in iPS cells: patent war looming? Read More »
There was a time, not so long ago, when the religious right hailed the discovery of induced pluripotent stem (iPS) cells. Headlines blared from the extreme right on the Internet such as, “Embryonic stem cells obsolete”. Even the same kind of thing, saying, “The stem cell debate is dead”. You see opponents of embryonic stem …
Why the extreme religious right are turning against iPS cells Read More »
One of my favorite stem cell scientists is Jeanne Loring of Scripps. She does great science and when you ask her questions, she frankly states her opinions and is clearly a gifted educator at heart too. Below is a Q&A interview I did with Jeanne on key issues of clinical translation of iPS cells. You …
Jeanne Loring interview: optimism on clinical translation of IPS cells Read More »
If you are wondering, “How will iPS cells get to help patients?” part of the answer is perhaps the big player and Japanese Institution, Riken and its arm Retina Institute of Japan. The stem cell field is still abuzz about induced pluripotent stem (iPS) cells 7 years after their discovery. This amazing embryonic stem cell-like cells can …
Meet Retina Institute of Japan: translating iPS cells Read More »
I recently did a Q&A interview with NeoStem CEO Dr. Robin Smith. I posted Part 1 of that interview a few days ago here. Now we have part two focused on VSEL, ES cells, and iPS cells. PK: I frequently have readers of my blog ask questions about VSEL. They seem puzzled and unsure of …
Interview with NeoStem CEO Robin Smith Part 2: VSEL, ES cells, and iPS cells Read More »
I’ve been running a poll on just how similar iPS cells are to ES cells. Most respondents do not think iPS cells are functionally identical to ES cells as only 18% said they were identical. Double that number say unequivocally that iPS cells are not functionally the same as ES cells. The greatest number of …
Results of stem cell poll: only 18% say iPS cells are functionally identical to ES cells Read More »
I’m doing this series called “The Elephant in the Lab” where I discuss controversial or taboo laboratory topics that people are usually too afraid to publicly discuss. I started with iPS cells (for a description and definition of iPS cells go here) and now have updated this post for 2013 because the field is changing rapidly. iPS …
One of the big issues related to using induced pluripotent stem (iPS) cells is cost. To make iPS cells from each patient for subsequent stem cell-based treatment would cost a fortune, by some estimates $200,000 or more per patient if done one-by-one. It could easily end up not being covered by insurances companies and Medicare, …
Yamanaka on making iPS cells from each patient: ‘in reality, we cannot do that’ Read More »